Compare West Pharmaceutical Services, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 22.89%
2
Company has a low Debt to Equity ratio (avg) at times
3
Healthy long term growth as Operating profit has grown by an annual rate 12.66%
4
Flat results in Jun 25
5
With ROE of 18.49%, it has a fair valuation with a 6.12 Price to Book Value
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 18,507 Million (Mid Cap)
33.00
NA
0.34%
-0.10
17.63%
6.32
Revenue and Profits:
Net Sales:
766 Million
(Quarterly Results - Jun 2025)
Net Profit:
132 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.82%
0%
10.82%
6 Months
-21.54%
0%
-21.54%
1 Year
-21.68%
0%
-21.68%
2 Years
-28.08%
0%
-28.08%
3 Years
-14.65%
0%
-14.65%
4 Years
-27.13%
0%
-27.13%
5 Years
17.68%
0%
17.68%
West Pharmaceutical Services, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.71%
EBIT Growth (5y)
12.66%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.98
Tax Ratio
20.26%
Dividend Payout Ratio
12.27%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
32.01%
ROE (avg)
22.89%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
6.12
EV to EBIT
27.17
EV to EBITDA
21.43
EV to Capital Employed
6.48
EV to Sales
5.61
PEG Ratio
NA
Dividend Yield
0.37%
ROCE (Latest)
23.86%
ROE (Latest)
18.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 147 Schemes (43.44%)
Foreign Institutions
Held by 370 Foreign Institutions (29.64%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
766.20
698.20
9.74%
Operating Profit (PBDIT) excl Other Income
199.60
168.40
18.53%
Interest
0.10
0.40
-75.00%
Exceptional Items
-3.10
-19.70
84.26%
Consolidate Net Profit
131.80
89.80
46.77%
Operating Profit Margin (Excl OI)
206.50%
183.90%
2.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 9.74% vs -6.72% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 46.77% vs -30.98% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,892.70
2,951.10
-1.98%
Operating Profit (PBDIT) excl Other Income
750.00
848.20
-11.58%
Interest
2.90
8.80
-67.05%
Exceptional Items
-19.00
-13.80
-37.68%
Consolidate Net Profit
492.70
593.40
-16.97%
Operating Profit Margin (Excl OI)
205.60%
240.90%
-3.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.98% vs 2.27% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -16.97% vs 1.28% in Dec 2023
About West Pharmaceutical Services, Inc. 
West Pharmaceutical Services, Inc.
Pharmaceuticals & Biotechnology
West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.
Company Coordinates 
Company Details
530 HERMAN O WEST DR , EXTON PA : 19341-1147
Registrar Details






